Peripheral nerve stimulation (PNS) offers significantly higher success rates (90-95%) compared to medications (40-60%) for neuropathy treatment, with fewer side effects and no risk of dependency. While medications like gabapentin and Lyrica provide short-term symptom relief, PNS addresses nerve dysfunction directly with long-lasting results. At Eagle Rock Neuropathy and Pain Center in Idaho Falls, patients who switch from medications to PNS report 70% average pain reduction within the first month, often eliminating or significantly reducing medication dependence. Medicare covers both treatments, but PNS provides superior long-term outcomes.
| Factor | PNS Therapy | Medications |
|---|---|---|
| Success Rate | 90-95% | 40-60% |
| Side Effects | Minimal (mild tingling) | Common (drowsiness, dizziness, weight gain) |
| Dependency Risk | None | Possible with opioids |
| Long-term Effectiveness | Sustained 5-10+ years | Often diminishes over time |
| Medicare Coverage | ✓ Covered | ✓ Covered |
| Daily Routine Impact | None (device works automatically) | Multiple daily doses required |
PNS targets nerve signals directly at the source, while medications work systemically through the bloodstream
Medications often lose effectiveness over time; PNS maintains consistent results for years
PNS has no drug interactions or organ toxicity concerns
Fine-tune stimulation settings instantly with a handheld controller
Eagle Rock Neuropathy and Pain Center in Idaho Falls helps patients transition from ineffective medications to proven PNS therapy with 90-95% success rates.
Schedule Free Consultation